Since The Cancer Genome Atlas (TCGA) study, EIF1AX mutations have been primarily reported in poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC), but also in well-differentiated thyroid carcinoma (WDTC) and benign thyroid nodules, although less frequently [12]. This evidence concerns the gene EIF1AX and differentiated thyroid carcinoma.